Chengdu Hyperway Pharmaceuticals, a startup biotech company located in Chengdu High Tech Development Zone, was founded in January 2019 by a group of high-caliber biotech entrepreneurs and industry veterans. Hyperway, adhering to a concept of "embracing all advances, attracting all talents and benefitting all people", is committed to discovering and developing FIC and BIC new medicines to address unmet medical needs using our state-of-art drug discovery technology platforms.

During the past four years, Hyperway has grown rapidly into a team of over 100 full-time employees. It is formed of talents attracted worldwide, and many of them have years of scientific and management experience in leading global or domestic pharmaceutical companies, such as Bayer, Bristol-Myers Squibb, Sanofi, Wuxi PharmaTech, and ChemPartner. Our core scientists are inventors of several first-in-class new drug candidates that are being used in clinical trials. Our scientific advisory team includes some of the most renowned scientists and experts in the pharmaceutical industry.

Within a short period of time, Hyperway has developed an impressive pipeline covering therapeutic areas of oncology, pain, and autoimmune diseases. 7 PCC have been identified and 4 IND applications have been completed, of which 3 have been approved by clinical trials and entered phase I clinical research. Among these, HBW-3220, a fully-owned novel 3rd generation BTK inhibitor of best-in-class potential, is being used in phase I clinical study involving patients with B-cell lymphoma.